## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%); PEG 1.62 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($232.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. ResMed stock price target lowered to $260 by Stifel on Philips return concerns**
- Source: Investing.com | 20251218T100845 | Somewhat-Bearish | Relevance: 100%
- Stifel has lowered its price target for ResMed (NYSE:RMD) to $260 from $270, maintaining a Hold rating, due to concerns about Philips' potential return to the U.S. CPAP market. The research firm estimates that ResMed's market share could drop by approximately 1,000 basis points upon Philips' re-entry, which is projected for late 2026. This adjustment comes despite solid fiscal year 2025 earnings growth for ResMed and varied analyst perspectives, with Baird downgrading the stock while UBS raised its price target.

**2. ResMed stock price target lowered to $260 by Stifel on Philips return concerns**
- Source: Investing.com UK | 20251218T095200 | Somewhat-Bearish | Relevance: 100%
- Stifel has reduced its price target on ResMed (NYSE:RMD) to $260.00 from $270.00, maintaining a Hold rating due to concerns about Philips' potential return to the U.S. CPAP market. The firm suggests ResMed's market share could fall by approximately 1,000 basis points, despite solid fiscal year 2025 earnings growth and strong financial health. ResMed's recent stock pullback is considered "intriguing," but a potential deceleration in fiscal year 2027 revenue growth could justify its current earnings multiple.

**3. Two Resmed leaders take the J.P. Morgan Healthcare Conference stage**
- Source: Stock Titan | 20251218T210839 | Neutral | Relevance: 100%
- Resmed (NYSE: RMD) announced that its chairman and CEO, Mick Farrell, and chief medical officer, Dr. Carlos Nunez, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at approximately 10:30 a.m. PST. A live audio-only webcast will be available via the investor website investor.resmed.com, with a replay accessible for 30 days after the event. The announcement further highlights Resmed's recent activities, including strong Q1 FY26 results and FDA clearance for an AI-enabled Smart Comfort feature.

**4. Stifel Nicolaus Adjusts ResMed Price Target to $260 From $270, Maintains Hold Rating**
- Source: marketscreener.com | 20251218T160828 | Somewhat-Bearish | Relevance: 100%
- Stifel Nicolaus has adjusted its price target for ResMed (RMD) to $260, down from $270, while reiterating a Hold rating on the stock. This update comes amidst other recent analyst adjustments for ResMed, including a downgrade by Baird and various price target changes from firms like Jefferies & Co, Wells Fargo, and Morgan Stanley. ResMed specializes in medical devices, masks, and software solutions for respiratory disorders, with a significant presence in the United States.

**5. Stifel Lowers Price Target for ResMed (RMD) to $260, Maintains H**
- Source: GuruFocus | 20251218T142421 | Somewhat-Bearish | Relevance: 100%
- Stifel has lowered its price target for ResMed (RMD) to $260 from $270, while maintaining a Hold rating. This adjustment follows several recent analyst rating changes for the respiratory care device company, which currently has an average target price of $293.23 from 15 analysts, implying a 19.23% upside from its current price. ResMed is recognized for its role in developing sleep apnea treatments, with significant market share in the Americas and other global regions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Stifel | $260 | $270 | -4% |
| 2025-12-16 | Baird | $275 | $300 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Stifel | main | Hold |
| 2025-12-16 | Baird | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 17 ($5.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.0M in recent transactions.
3. Elevated short interest (8.2%): bears positioning against stock.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.62 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $35.8B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.62 |
| Forward P/E | 20.4 |
| Current P/E | 22.5 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.3% to -1.6% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.6pp (needs >3.0% for momentum thesis). Below SMA200 (0.97x), long-term trend not supportive. RSI neutral at 42. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.62% (CS: 27) | Neutral |
| RSI_14 | 41.9 | Neutral |
| MACD Histogram | -0.46 | Bearish |
| vs SMA20 | 0.977x | Below |
| vs SMA50 | 0.964x | Below |
| vs SMA200 | 0.966x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $245.01
- **Stop Loss:** $232.97 (4.9% risk)
- **Target:** $257.05 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 99
- **Position Value:** $24,255.99
- **Portfolio %:** 24.26%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*